BAYN Stock Analysis: Bayer NA | XETRA
Drug Manufacturers - General | XETRA, Germany | Market Cap: 48.365m EUR | 12M Return: 73.6% | DE000BAY0017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 92.8M
EPS Trend: -78.7%
Qual. Beats: 2
Rev. Trend: -98.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bayer AG is a German life sciences company headquartered in Leverkusen that operates across three core segments: Pharmaceuticals, Consumer Health, and Crop Science. This structure makes Bayer unusual among major healthcare companies, as it combines human pharmaceutical and consumer health businesses with a sizable agricultural inputs business, giving it exposure to both healthcare demand and global food production trends.
The Pharmaceuticals segment focuses on prescription drugs in cardiology, womens health, oncology, hematology, and ophthalmology, and also includes diagnostic imaging agents and emerging areas such as cell and gene therapy. The Consumer Health segment sells over-the-counter medicines, nutritional supplements, and products in categories including allergy, cough and cold, dermatology, pain, and digestive health. The Crop Science segment supplies chemical and biological crop protection, improved plant traits, seeds, digital farming solutions, and pest and weed management services to agricultural customers.
Bayer distributes its products through a mix of channels, including wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, hospitals, and direct sales to farmers. The company was founded in 1863 and is listed on the XETRA exchange under the ticker BAYN, with a large-cap market capitalization. As a German-listed pharmaceutical major, Bayer is a constituent of major European equity benchmarks, and its integrated crop science business places it among the worlds largest players in seeds and crop protection.
- Glyphosate litigation reserves and Roundup verdicts pressure earnings outlook
- Pharmaceutical pipeline approvals and Eylea franchise drive segment revenue growth
- Crop Science margins pressured by lower glyphosate pricing and US acreage decline
- Monsanto debt deleveraging remains key capital allocation priority
| Net Income: -1.74b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -3.01 > 1.0 |
| NWC/Revenue: 3.03% < 20% (prev 8.60%; Δ -5.57% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.16b > Net Income -1.74b |
| Net Debt (33.6b) to EBITDA (5.08b): 6.63 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (982.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 59.05% > 18% (prev 54.95%; Δ 4.10% > 0.5%) |
| Asset Turnover: 42.70% > 50% (prev 43.88%; Δ -1.17% > 0%) |
| Interest Coverage Ratio: 0.52 > 6 (EBIT TTM 1.33b / Interest Expense TTM 2.55b) |
| A: 0.01 (Total Current Assets 33.6b - Total Current Liabilities 32.3b) / Total Assets 107b |
| B: 0.06 (Retained Earnings 6.73b / Total Assets 107b) |
| C: 0.01 (EBIT TTM 1.33b / Avg Total Assets 106b) |
| D: 0.38 (Book Value of Equity 29.6b / Total Liabilities 77.6b) |
| Altman-Z'' = 0.77 = B |
| DSRI: 1.04 (Receivables 14.9b/14.6b, Revenue 45.4b/46.2b) |
| GMI: 0.93 (GM 54.95% / 59.05%) |
| AQI: 1.01 (AQ_t 0.57 / AQ_t-1 0.56) |
| SGI: 0.98 (Revenue 45.4b / 46.2b) |
| TATA: -0.05 (NI -1.74b - CFO 4.16b) / TA 107b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of August 18, 2026, the stock is trading at EUR 47.90 with a total of 1,044,809 shares traded. Over the past week, the price has changed by -2.70%, over one month by -1.16%, over three months by +26.62% and over the past year by +73.61%.
Current recommended Stop Loss: 46.30 (which is 3.3% or 1.2 ATR below the current price).
Bayer NA has no consensus analysts rating.
P/E Forward = 11.1732
P/S = 1.0659
P/B = 1.6541
P/EG = 4.7193
Revenue TTM = 45.4b EUR
EBIT TTM = 1.33b EUR
EBITDA TTM = 5.08b EUR
Long Term Debt = 30.8b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 5.63b EUR (from shortTermDebt, last fiscal year)
Debt = 38.7b EUR (from shortLongTermDebtTotal, last fiscal year) + Leases 1.29b
Net Debt = 33.6b EUR (calculated: Debt 38.7b - CCE 5.08b)
Enterprise Value = 82.0b EUR (48.4b + Debt 38.7b - CCE 5.08b)
Interest Coverage Ratio = 0.52 (Ebit TTM 1.33b / Interest Expense TTM 2.55b)
EV/FCF = 56.56x (Enterprise Value 82.0b / FCF TTM 1.45b)
FCF Yield = 1.77% (FCF TTM 1.45b / Enterprise Value 82.0b)
FCF Margin = 3.20% (FCF TTM 1.45b / Revenue TTM 45.4b)
Net Margin = -3.83% (Net Income TTM -1.74b / Revenue TTM 45.4b)
Gross Margin = 59.05% ((Revenue TTM 45.4b - Cost of Revenue TTM 18.6b) / Revenue TTM)
Gross Margin QoQ = 58.24% (prev 60.97%)
Tobins Q-Ratio = 0.76 (Enterprise Value 82.0b / Total Assets 107b)
Interest Expense / Debt = 6.58% (Interest Expense 2.55b / Debt 38.7b)
Taxrate = 28.66% (92.0m / 321.0m)
NOPAT = 946.7m (EBIT 1.33b * (1 - 28.66%))
Current Ratio = 1.04 (Total Current Assets 33.6b / Total Current Liabilities 32.3b)
Debt / Equity = 1.31 (Debt 38.7b / totalStockholderEquity, last quarter 29.6b)
Debt / EBITDA = 6.63 (Net Debt 33.6b / EBITDA 5.08b)
Debt / FCF = 23.20 (Net Debt 33.6b / FCF TTM 1.45b)
Total Stockholder Equity = 28.5b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.64% (Net Income -1.74b / Total Assets 107b)
RoE = -6.10% (Net Income TTM -1.74b / Total Stockholder Equity 28.5b)
RoCE = 2.24% (EBIT 1.33b / Capital Employed (Equity 28.5b + L.T.Debt 30.8b))
RoIC = 1.21% (NOPAT 946.7m / Invested Capital 78.4b)
WACC = 6.35% (E(48.4b)/V(87.1b) * Re(7.67%) + D(38.7b)/V(87.1b) * Rd(6.58%) * (1-Tc(0.29)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 8.70 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈2.71b ; Y1≈2.37b ; Y5≈1.92b
[DCF] Fair Price = N/A (negative equity: EV 30.8b - Net Debt 33.6b = -2.85b; debt exceeds intrinsic value)
EPS Correlation: -78.70 | EPS CAGR: -8.76% | SUE: 0.90 | # QB: 2
Revenue Correlation: -98.54 | Revenue CAGR: -1.97% | SUE: 1.00 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=-6.50% | Revisions=-17% | Analysts=6
EPS current Year (2026-12-31): EPS=4.46 | Chg30d=+0.91% | Revisions=+58% | GrowthEPS=-9.1% | GrowthRev=+0.3%
EPS next Year (2027-12-31): EPS=4.73 | Chg30d=+0.93% | Revisions=+25% | GrowthEPS=+5.9% | GrowthRev=+2.7%
[Analyst] Revisions Ratio: +38% (up=15, down=6)